Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2016

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2016
Published Aug 24, 2016
267 pages — Published Aug 24, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2016, provides an overview of the Wet (Neovascular / Exudative) Macular Degeneration pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Wet (Neovascular / Exudative) Macular Degeneration, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Wet (Neovascular / Exudative) Macular Degeneration
- The report reviews pipeline therapeutics for Wet (Neovascular / Exudative) Macular Degeneration by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Wet (Neovascular / Exudative) Macular Degeneration therapeutics and enlists all their major and minor projects
- The report assesses Wet (Neovascular / Exudative) Macular Degeneration therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Wet (Neovascular / Exudative) Macular Degeneration


Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Wet (Neovascular / Exudative) Macular Degeneration
- Identify potential new clients or partners in the target demographic
- Develop

  
Source:
Document ID
GMDHC8376IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents214
  List of Tables132
  List of Figures151
Introduction161
  Global Markets Direct Report Coverage161
Wet (Neovascular / Exudative) Macular Degeneration Overview171
Therapeutics Development181
  Pipeline Products for Wet (Neovascular / Exudative) Macular Degeneration Overview181
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics under Development by Companies194
Wet (Neovascular / Exudative) Macular Degeneration Pipeline Products Glance233
  Late Stage Products231
  Clinical Stage Products241
  Early Stage Products251
Wet (Neovascular / Exudative) Macular Degeneration Products under Development by Companies266
Wet (Neovascular / Exudative) Macular Degeneration Companies Involved in Therapeutics Development3251
  Aciont Inc.321
  Adverum Biotechnologies, Inc.331
  Allergan Plc341
  Alteogen Inc.351
  Amakem NV361
  Ampio Pharmaceuticals, Inc.371
  Apellis Pharmaceuticals, Inc.381
  Apexigen, Inc.391
  Applied Genetic Technologies Corporation401
  Benitec Biopharma Limited411
  Boehringer Ingelheim GmbH421
  Cell Medica Limited431
  Charlesson LLC.441
  Cipla Ltd.451
  Clanotech AB461
  Clearside BioMedical, Inc.471
  Clonz Biotech Private Limited481
  Coherus BioSciences, Inc.491
  Daiichi Sankyo Company, Limited501
  Diffusion Pharmaceuticals Inc.511
  Eleven Biotherapeutics Inc.521
  Exonate Limited531
  F. Hoffmann-La Roche Ltd.541
  Formycon AG551
  Graybug Vision Inc561
  GTx, Inc.571
  iCo Therapeutics Inc.581
  Icon Bioscience, Inc.591
  Iconic Therapeutics, Inc.601
  Kala Pharmaceuticals, Inc.611
  Kodiak Sciences Inc.621
  Mabion SA631
  MeiraGTx Limited641
  Mitotech S.A.651
  Ocular Therapeutix, Inc.661
  Ohr Pharmaceutical Inc.671
  Ophthotech Corp.681
  Oxford BioMedica Plc691
  PanOptica, Inc.701
  Pfenex Inc.711
  Pfizer Inc.721
  pSivida Corp.731
  Regeneron Pharmaceuticals Inc741
  RegenxBio Inc.751
  RXi Pharmaceuticals Corporation761
  Santen Pharmaceutical Co., Ltd.771
  Sanwa Kagaku Kenkyusho Co., Ltd.781
  TRACON Pharmaceuticals, Inc.791
  TWi Pharmaceuticals, Inc.801
  Tyrogenex, Inc.811
  Xbrane Biopharma AB821
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Assessment8313
  Assessment by Monotherapy Products831
  Assessment by Combination Products841
  Assessment by Target853
  Assessment by Mechanism of Action884
  Assessment by Route of Administration922
  Assessment by Molecule Type942
Drug Profiles96155
  (aflibercept + nesvacumab) Drug Profile961
  (aflibercept + rinucumab) Drug Profile971
  A-006 Drug Profile981
  abicipar pegol Drug Profile993
  AC-301 Drug Profile1021
  ACX-107 Drug Profile1031
  aflibercept Drug Profile1049
  aflibercept biosimilar Drug Profile1131
  aflibercept biosimilar Drug Profile1141
  AGN-151200 Drug Profile1152
  ALG-1001 Drug Profile1173
  AMA-0428 Drug Profile1201
  APL-2 Drug Profile1212
  APX-003 Drug Profile1231
  APX-3330 Drug Profile1242
  AVA-101 Drug Profile1263
  AVA-201 Drug Profile1291
  avacincaptad pegol sodium Drug Profile1302
  axitinib Drug Profile1322
  AXT-108 Drug Profile1341
  bertilimumab Drug Profile1354
  Beta-LGND2 Drug Profile1392
  BI-144807 Drug Profile1411
  brolucizumab Drug Profile1422
  C-16Y Drug Profile1441
  CBT-128 Drug Profile1451
  CLT-005 Drug Profile1461
  CLT-28643 Drug Profile1471
  cyclosporine Drug Profile1481
  DA-3131 Drug Profile1491
  danazol Drug Profile1504
  DE-120 Drug Profile1541
  DNX-214 Drug Profile1551
  Doxarubicin Pegylated Drug Profile1561
  Drug for Age Related Macular Degeneration Drug Profile1571
  DS-7080 Drug Profile1581
  ENV-1305 Drug Profile1591
  GB-101 Drug Profile1601
  Gene Therapy 1 for Wet Age-Related Macular Degeneration Drug Profile1611
  Gene Therapy for Wet Age-related Macular Degeneration Drug Profile1621
  hI-con1 Drug Profile1632
  IVMED-50 Drug Profile1651
  IVMED-55 Drug Profile1661
  K-106 Drug Profile1671
  KSI-201 Drug Profile1681
  LHA-510 Drug Profile1691
  Monoclonal Antibody to Inhibit VEGF for Wet Age Related Macular Degeneration Drug Profile1701
  OCU-200 Drug Profile1711
  OLX-301 Drug Profile1721
  ONL-1204 Drug Profile1731
  OPT-302 Drug Profile1744
  OXB-201 Drug Profile1782
  PAN-90806 Drug Profile1802
  pegpleranib sodium Drug Profile1823
  PF-05206388 Drug Profile1852
  PF-655 Drug Profile1872
  plastoquinone decyl triphenylphosphonium bromide Drug Profile1892
  Protein to Inhibit VEGF for Wet Age Related Macular Degeneration Drug Profile1911
  ranibizumab Drug Profile1926
  ranibizumab biosimilar Drug Profile1981
  ranibizumab biosimilar Drug Profile1991
  ranibizumab biosimilar Drug Profile2002
  ranibizumab biosimilar Drug Profile2021
  ranibizumab biosimilar Drug Profile2031
  ranibizumab biosimilar Drug Profile2041
  ranibizumab biosimilar Drug Profile2051
  Recombinant Protein for Age Related Macular Degeneration Drug Profile2061
  Recombinant Proteins to Inhibit VEGF for Wet Age Related Macular Degeneration Drug Profile2071
  RES-529 Drug Profile2084
  RG-7716 Drug Profile2121
  RGX-314 Drug Profile2132
  RXI-109 Drug Profile2156
  SK-1011 Drug Profile2211
  Small Molecule for Wet AMD and Dry AMD Drug Profile2221
  Small Molecules for Dry and Wet Age Related Macular Degeneration Drug Profile2231
  Small Molecules to Inhibit SRPK-1 for Wet Macular Degeneration Drug Profile2241
  SPHINX-31 Drug Profile2251
  squalamine lactate Drug Profile2268
  sunitinib malate Drug Profile2342
  Synthetic Peptides to Inhibit VEGF for Wet Adult Macular Degeneration Drug Profile2361
  TRC-105 Drug Profile2378
  triamcinolone acetonide Drug Profile2451
  TT-211 Drug Profile2461
  TT-231 Drug Profile2471
  X-82 Drug Profile2483
Wet (Neovascular / Exudative) Macular Degeneration Dormant Projects2514
Wet (Neovascular / Exudative) Macular Degeneration Discontinued Products2551
Wet (Neovascular / Exudative) Macular Degeneration Product Development Milestones25610
  Featured News &Press Releases2561
    Jul 25, 2016: Opthea Reports Positive Data From Wet AMD Clinical Trial2561
    Jul 25, 2016: Opthea to Host Conference Call Providing Update on Phase 1 Wet AMD Clinical Trial With OPT-3022571
    Jul 07, 2016: Adverum Biotechnologies Provides wet AMD Program Update2581
    Jun 20, 2016: Ophthotech Completes Patient Recruitment in Phase 3 Trial of Fovista Anti-PDGF Therapy in Combination with Eylea or Avastin in Wet Age-Related Macular Degeneration2581
    Jun 07, 2016: Xbrane Biopharma Initiates Scale-Up of Production of its Ranibizumab Biosimilar Xlucane Ahead of Plan2591
    May 25, 2016: Regeneron Announces Important US Prescribing Information Clarification for EYLEA (aflibercept) Injection2591
    May 05, 2016: Opthea Doses First Patient in Phase 2A Dose Expansion Study for OPT-302 in Wet AMD2601
    May 04, 2016: Graybug Vision GB-102 Toxicology/PK Study Presented at ARVO 20162601
    May 02, 2016: Ohr Pharmaceutical Announces Appointment of David Brown, MD as Chair of Phase 3 Clinical Program Steering Committee2611
    May 02, 2016: Graybug Vision Collaborator Dr. Peter Campochiaro Presented at ARVO 20162621
    Apr 27, 2016: Ohr Pharmaceutical Announces Presentation on Squalamine Lactate at the 2016 Association for Research in Vision and Ophthalmology Conference in Seattle, WA2631
    Apr 25, 2016: Ophthalmology Product Company Graybug Vision to Present Data at ARVO 20162631
    Apr 21, 2016: Opthea Phase 1 Wet AMD Clinical Trial With OPT-302 Meets Primary Safety Objective2641
    Apr 18, 2016: Ohr Pharmaceutical, Inc. Announces Enrollment of First Patient in Phase III Wet AMD Clinical Program2641
    Mar 30, 2016: Opthea Completes Patient Enrolment for OPT - 302 Phase 1 Dose Escalation Trial in Patients with Wet AMD2651
Appendix2662
  Methodology2661
  Coverage2661
  Secondary Research2661
  Primary Research2661
  Expert Panel Validation2661
  Contact Us2661
  Disclaimer2671

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2016" Aug 24, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Wet-Neovascular-Exudative-Macular-Degeneration-Pipeline-Review-H2-2016-2088-16418>
  
APA:
Global Markets Direct - Market Research. (2016). Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2016 Aug 24, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Wet-Neovascular-Exudative-Macular-Degeneration-Pipeline-Review-H2-2016-2088-16418>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.